Po Y. Ho

Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy

Amira Barkal, Kipp Weiskopf, Kevin S. Kao et al. · Nature Immunology · 2017 · 533 citations · Full text

Cancer Immunosurveillance, Mhc Class, Immunology +8

Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer

Lawrence Fong, Andrew Hotson, John D. Powderly et al. · Cancer Discovery · 2019 · 321 citations · Full text

Macrophages eat cancer cells using their own calreticulin as a guide: Roles of TLR and Btk

Mingye Feng, James Y. Chen, Rachel Weissman-Tsukamoto et al. · Proceedings of the National Academy of Sciences · 2015 · 254 citations · Full text

A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer

Paola Betancur, Brian J. Abraham, Ying Ying Yiu et al. · Nature Communications · 2017 · 222 citations · Full text

A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti–PD-(L)1 and Anti–CTLA-4 in Preclinical Models

Stephen B. Willingham, Po Y. Ho, Andrew Hotson et al. · Cancer Immunology Research · 2018 · 209 citations